CervoMed Inc (NASDAQ: CRVO) on Monday, plunged -14.85% from the previous trading day, before settling in for the closing price of $7.11. Within the past 52 weeks, CRVO’s price has moved between $1.80 and $20.63.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 56.66%. The company achieved an average annual earnings per share of 0.77%. With a float of $5.63 million, this company’s outstanding shares have now reached $8.70 million.
Let’s determine the extent of company efficiency that accounts for 15 employees. In terms of profitability, gross margin is 100.0%, operating margin of -636.52%, and the pretax margin is -567.67%.
CervoMed Inc (CRVO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CervoMed Inc is 35.25%, while institutional ownership is 26.22%. The most recent insider transaction that took place on May 14 ’25, was worth 35,811. In this transaction CFO, GC & Secretary of this company bought 4,233 shares at a rate of $8.46, taking the stock ownership to the 5,500 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CFO & GC bought 1,000 for $18.16, making the entire transaction worth $18,160. This insider now owns 1,267 shares in total.
CervoMed Inc (CRVO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.31% during the next five years compared to 56.66% growth over the previous five years of trading.
CervoMed Inc (NASDAQ: CRVO) Trading Performance Indicators
CervoMed Inc (CRVO) is currently performing well based on its current performance indicators. A quick ratio of 9.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -1.77 in one year’s time.
Technical Analysis of CervoMed Inc (CRVO)
Looking closely at CervoMed Inc (NASDAQ: CRVO), its last 5-days average volume was 0.22 million, which is a drop from its year-to-date volume of 2.51 million. As of the previous 9 days, the stock’s Stochastic %D was 41.64%.
During the past 100 days, CervoMed Inc’s (CRVO) raw stochastic average was set at 27.50%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.87% in the past 14 days, which was lower than the 203.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.26, while its 200-day Moving Average is $8.06. However, in the short run, CervoMed Inc’s stock first resistance to watch stands at $6.75. Second resistance stands at $7.45. The third major resistance level sits at $7.80. If the price goes on to break the first support level at $5.70, it is likely to go to the next support level at $5.35. Now, if the price goes above the second support level, the third support stands at $4.65.
CervoMed Inc (NASDAQ: CRVO) Key Stats
Market capitalization of the company is 52.65 million based on 8,703K outstanding shares. Right now, sales total 9,740 K and income totals -16,290 K. The company made 1,920 K in profit during its latest quarter, and -4,890 K in sales during its previous quarter.
